AngioGenex, Inc. (BULLETIN BOARD: AGGX.OB) a New York based biotechnology company, has been approved for trading on the Frankfurt Stock Exchange (FSE) market under the symbol “TLE.” The Frankfurt Stock Exchange (WB(R) Frankfurter Wertpapierborse) is one of the world’s most active trading centers for securities and the largest of the German stock exchanges. As an [...]

CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) announced that it will present a session on protein angiogenesis for the treatment of cardiovascular disease at the Euro-Biotech Forum, taking place in Paris from June 26-28, 2007. The presentation, titled “New Progress in Protein Angiogenesis Therapy for Cardiovascular Disease Patients,” will be given by Dr. Jack Jacobs, vice president and [...]

Vical Incorporated (NASDAQ:VICL) announced that the company’s licensee, AnGes MG, Inc. reported positive results following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of an angiogenesis product candidate using Vical’s DNA delivery technology. Based on the findings that the primary efficacy endpoint in the trial had been achieved [...]

Vegenics Limited and CoGenesys, Inc. announced that Vegenics has licensed from CoGenesys exclusive worldwide rights to human monoclonal antibodies that target vascular endothelial growth factor-C (VEGF-C). VEGF-C is believed to play an important role in promoting the formation of new blood vessels and the maintenance of existing blood vessels. In oncology, inhibition of VEGF-C is [...]

Scientists discuss in “Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization” new findings in angiogenesis. In this recently published article, scientists in the United States conducted a study “To test whether a direct antiangiogenic peptide (anginex) and a vascular endothelial growth factor antibody (bevacizumab, Avastin) can transiently normalize [...]

Current study results from the report, “Opposite effects of WEB2086 on angiogenesis in atheromas and ischemic hindlimb of apoE gene deficient mice,” have been published. “Our previous research has suggested that platelet activating factor receptor was related to atherosclerosis. The present study investigated the effect of a platelet activating factor receptor antagonist-WEB2086 on angiogenesis in [...]

Current study results from the report, “ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis,” have been published. “Melanoma is a very aggressive and highly angiogenic tumor in which standard treatments have had only limited success. Patients with advanced disease have a 5-year survival rate of 5%,” scientists in [...]

Investigators publish new data in the report “Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. Prostaglandin E2 (PGE(2)), a major product of cyclooxygenase, exerts its functions by binding to four G protein-coupled receptors (EP1-4) and has been implicated in modulating angiogenesis. The present study examined the role of the [...]

A report, “Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens,” is newly published data in Atherosclerosis. “Treatment with statins is considered a first line therapy in atherosclerotic disease. Intraplaque angiogenesis is involved in plaque progression and instability,” researchers in Athens, Greece report.
“It remains unclear whether the beneficial effect of statin treatment in [...]

Research findings, “Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells,” are discussed in a new report. “Inhibition of endothelial cell proliferation and angiogenesis is emerging as an important strategy in cancer therapeutics. Kringle 5 (K5) of human plasminogen is a potent angiogenesis inhibitor,” investigators in the [...]